Association of annexin A10 expression with poor prognosis of intrahepatic cholangiocarcinoma

Abstract

Background Annexin A10 expression influences the prognosis of several gastrointestinal cancers. We explored the association of annexin A10 expression with the overall survival (OS) of patients who underwent curative surgery for cholangiocarcinoma. Methods Patients who underwent curative surgery for cholangiocarcinoma (except gallbladder cancer) and had pathological stage T1-3N0M0 disease were enrolled. Annexin A10 expression was examined by performing immunohistochemical staining. Patient demographics and survival outcome data were retrieved from medical records. Results In total, 185 patients were enrolled. The primary tumor location was intrahepatic and extrahepatic (including the perihilar region) for 89% and 11% of patients, respectively. Positive annexin A10 staining was detected for 61 (33%) patients and associated with extrahepatic or perihilar cholangiocarcinoma (p = 0.001) and lower histological grade (p < 0.001). Patients with positive annexin A10 staining exhibited significantly poorer survival relative to patients with negative staining results (median OS, 2.5 vs. 4.9 years, p = 0.025). In the multivariate analysis adjusting for age, sex, tumor location, tumor grade, hepatitis infection, and disease stage, positive annexin A10 remained an independent predictor of poor OS (hazard ratio 1.572, p = 0.034). In the subgroup analysis, the association between annexin A10 and prognosis was restricted to intrahepatic cholangiocarcinoma. Among patients with intrahepatic cholangiocarcinoma, patients with positive annexin A10 staining exhibited significantly poorer survival compared with patients with negative annexin A10 staining (median OS, 2.3 vs. 4.9 years, p = 0.008). Conclusion Positive annexin A10 expression was associated with poor prognosis of intrahepatic cholangiocarcinoma.

Pathobiological functions and clinical implications of annexin dysregulation in human cancers

“…Moreover, ANXA10 promoted growth of ESCC cell lines via activation of Akt and ERK1/2 pathways ( Kodaira et al, 2019 ). ANXA10 expression was also correlated with poor overall survival in colorectal cancer ( Bae et al, 2015 ), and intrahepatic cholangiocarcinoma ( Shao et al, 2022 ). In addition, ANXA10 expression was found upregulated in primary and metastatic melanoma and associated with tumor progression, observations reinforced by its promoting role of cell migration in vitro and metastases in vivo ( Zhang X. et al, 2021 ).…”

Evaluation of Annexins Family as Potential Biomarker for Predicting Progression and Prognosis in Clear Renal Cell Carcinoma

“…Annexins, including 12 family members, play a major role in the regulation of a broad range of physiological processes linked to cellular membranes [3]. Previous studies have revealed that the aberrant expression of ANXAs is frequently observed in various types of cancer, including cervical cancer [4], bladder cancer [5,6], breast cancer [7][8][9], gastric cancer [10], lung cancer [11,12], oral squamous cell carcinoma [13], hepatocellular carcinoma [14,15], and cholangiocarcinoma [16]. ANXAs may function as either oncogenes or suppressors depending on tumour biology.…”